Witnessing the stock’s movement on the chart, on Thursday, Terns Pharmaceuticals Inc (NASDAQ: TERN) had a quiet start as it plunged -2.81% to $4.50, before settling in for the price of $4.63 at the close. Taking a more long-term approach, TERN posted a 52-week range of $4.32-$11.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -25.00%. Meanwhile, its Annual Earning per share during the time was -12.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.25%. This publicly-traded company’s shares outstanding now amounts to $84.92 million, simultaneously with a float of $62.32 million. The organization now has a market capitalization sitting at $382.22 million. At the time of writing, stock’s 50-day Moving Average stood at $6.13, while the 200-day Moving Average is $6.93.
Terns Pharmaceuticals Inc (TERN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Terns Pharmaceuticals Inc’s current insider ownership accounts for 26.63%, in contrast to 71.52% institutional ownership. According to the most recent insider trade that took place on Jan 02 ’25, this organization’s Chief Medical Officer sold 4,481 shares at the rate of 5.71, making the entire transaction reach 25,607 in total value, affecting insider ownership by 54,269. Preceding that transaction, on Jan 06 ’25, Company’s Chief Financial Officer sold 9,059 for 5.80, making the whole transaction’s value amount to 52,500. This particular insider is now the holder of 74,752 in total.
Terns Pharmaceuticals Inc (TERN) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
Terns Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 6.25% and is forecasted to reach -1.32 in the upcoming year.
Terns Pharmaceuticals Inc (NASDAQ: TERN) Trading Performance Indicators
Let’s observe the current performance indicators for Terns Pharmaceuticals Inc (TERN). It’s Quick Ratio in the last reported quarter now stands at 32.99. The Stock has managed to achieve an average true range (ATR) of 0.36.
In the same vein, TERN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.18, a figure that is expected to reach -0.30 in the next quarter, and analysts are predicting that it will be -1.32 at the market close of one year from today.
Technical Analysis of Terns Pharmaceuticals Inc (TERN)
Going through the that latest performance of [Terns Pharmaceuticals Inc, TERN]. Its last 5-days volume of 1.67 million indicated improvement to the volume of 1.62 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 5.99% While, its Average True Range was 0.33.
Raw Stochastic average of Terns Pharmaceuticals Inc (TERN) in the period of the previous 100 days is set at 0.00%, which indicates a major rise in contrast to 0.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.15% that was lower than 76.73% volatility it exhibited in the past 100-days period.
